Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
CC1083610
- Development stage
- Unknown
- Lead developer
- Bristol Myers Squibb
01
Overview
CC1083610 is an investigational drug being evaluated in early-phase clinical trials for metastatic castration-resistant prostate cancer. It is administered as part of a combination regimen with other experimental agents (CC-94676 and CC1083611) in a Phase 1, multi-center, open-label, dose-finding study designed to assess safety, tolerability, pharmacokinetics, and preliminary efficacy. The precise mechanism of action and molecular target(s) for CC1083610 have not been disclosed publicly. The drug is under development by Bristol-Myers Squibb (BMS), with Celgene also listed as a sponsor in some trial records[2][3][5][7].
Beyond the preview
Go deeper on CC1083610.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on CC1083610.